argenx (ARGX) to Release Earnings on Thursday

argenx (NASDAQ:ARGX) will likely be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect argenx to post earnings of $0.98 per share and revenue of $682.05 million for the quarter.

argenx Stock Up 1.1 %

ARGX opened at $647.49 on Friday. argenx has a twelve month low of $349.86 and a twelve month high of $678.21. The company has a fifty day moving average of $642.31 and a 200-day moving average of $585.45. The stock has a market cap of $39.34 billion, a PE ratio of -735.78 and a beta of 0.58.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ARGX. HC Wainwright reiterated a “buy” rating and set a $717.00 price objective (up from $670.00) on shares of argenx in a research report on Tuesday, January 14th. Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and raised their price target for the stock from $439.00 to $715.00 in a report on Tuesday, November 5th. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft cut shares of argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th. Finally, JMP Securities raised their price target on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.